Clinical breakthroughs cannot secure a market path if patients cannot tolerate the safety trade-offs.
Treatments carrying superior clinical and biological efficacy frequently face commercial and regulatory resistance if they trigger severe, intolerable toxicities or side effects.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
Meeting the primary efficacy metric of PFS failed to secure a clear path for Zynlonta due to the unacceptable safety signal of a 3-to-1 death imbalance.
Despite being safe, the drug’s high-stakes clinical trial failed entirely to show a functional advantage when evaluated alongside contemporary standard-of-care baseline treatments.
Numerical efficacy milestones in obesity weight loss were completely overshadowed by severe, commercially unviable gastrointestinal side effects.